Concord Biotech Q1 revenues fall 5% on facility costs

Concord Biotech reported Q1 FY26 revenues of INR 204 crores, down 5% year-on-year due to commercialization costs from its new injectable facility in Valthera. API revenues fell 10% to INR 153 crores, while formulation business grew 12% to INR 50.2 crores.

EBITDA stood at INR 61 crores with margins at 30.1%, impacted by the new facility's start-up costs. Excluding these costs, EBITDA margins were approximately 37%.

The company received US FDA approvals for teriflunomide tablets and incorporated subsidiaries in the US and India to strengthen market presence.